Pricing Log in Create free account
Saturday 31 October 2026 Export GILD’s income statement to Excel — free account

Gilead Sciences, Inc.

GILD Healthcare Drug Manufacturers General

Gilead Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $29.4 billion, up 2.40% from fiscal 2024. In the quarter to June 2026, revenue grew 10.2%, EPS fell 638.2%, free cash flow grew 376.8% and total debt rose 5.21%, each against the same quarter a year earlier. Member of the S&P 500 and Nasdaq 100; dividend growth for ten consecutive years.

170.84 5.23 +3.16%
Market cap
$205.4B
P/E
0.0×
Fwd P/E
−45.5×
Dividend yield
1.90%
F-score
8/9
Altman Z
4.03
Beneish M
−2.45
Dividend safety
77/100
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Filings

Gilead Sciences, Inc. 10-Q filed Oct 30, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 8:09 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 6, 2026: 11 added · 7 removed · 35 modified; 13 with only figures updated; 2 moved without change

  1. Added · Virology

    •In October 2026, the Centers for Medicare and Medicaid Services completed the process of setting the Maximum Fair Price for Biktarvy under Medicare. The new price will be effective and impact our Biktarvy revenue starting January 1, 2028.